Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
2.465(c) 2.48(c) 2.54(c) 2.57(c) 2.45(c) Last
165 387 51 516 73 858 141 253 78 020 Volume
-3.33% +0.61% +2.42% +1.18% -4.67% Change
More quotes
Estimated financial data (e)
Sales 2021 11,1 M 13,0 M 13,0 M
Net income 2021 -27,0 M -31,6 M -31,6 M
Net cash position 2021 44,7 M 52,4 M 52,4 M
P/E ratio 2021 -8,75x
Yield 2021 -
Sales 2022 8,10 M 9,49 M 9,49 M
Net income 2022 -32,5 M -38,1 M -38,1 M
Net cash position 2022 12,7 M 14,9 M 14,9 M
P/E ratio 2022 -7,42x
Yield 2022 -
Capitalization 239 M 280 M 280 M
EV / Sales 2021 17,5x
EV / Sales 2022 27,9x
Nbr of Employees 139
Free-Float 51,4%
More Financials
Company
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The... 
More about the company
Ratings of Transgene
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about TRANSGENE
09/23Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 23..
CI
09/16TRANSGENE : Gastrointestinal Cancer Drug Study Confirms Potential of Cancer-Killing Virus
MT
09/16Transgene Presents Data from Phase I Clinical Trial Confirming the Potential of the Onc..
CI
09/13GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
09/07PRESS RELEASE : CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) AAV manufa..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01Transgene Participates in New Cancer Research Consortium
CI
06/28Transgene Announces Update on Phase I Clinical Trial of TG4050
CI
06/25GLOBAL MARKETS LIVE : Facebook, Toshiba, Fedex, Nike, Microsoft...
06/24Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg400..
CI
06/22GLOBAL MARKETS LIVE : Netflix, Boeing, Tesla, Delta Air Lines, Blackstone Resources....
06/22TRANSGENE : Raises $40.6 Million in Share Sale; Stock Falls 7%
MT
06/22TRANSGENE : Admission of new securities
CO
06/08Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses En..
CI
05/27BioInvent, Transgene Win US FDA Nod For Phase 1/2a Study of Cancer Vaccine
MT
More news
News in other languages on TRANSGENE
09/23Les valeurs à suivre aujourd'hui à la Bourse de paris Jeudi 23 septembre 2021
09/23STOCK MARKET PARIS : Il paraît que la Fed a parlé
09/23EN DIRECT DES MARCHES : Capgemini, Trigano, Valneva, GTT, Nicox, GSK, Facebook, Boeing, Ch..
09/22Les valeurs à suivre demain à la Bourse de Paris - Jeudi 23 septembre 2021
09/22TRANSGENE : creuse ses pertes
More news
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,45 €
Average target price 3,80 €
Spread / Average Target 55,1%
EPS Revisions
Managers and Directors
Hedi Ben Brahim Chairman & Chief Executive Officer
Jean-Philippe Del Chief Financial Officer
Eric Quéméneur Chief Scientific Officer & Executive VP
Hemanshu Shah VP-Medical Affairs & International Development
Maud Brandely VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
TRANSGENE55.95%294
GILEAD SCIENCES, INC.23.05%89 886
BIONTECH SE333.01%85 255
WUXI APPTEC CO., LTD.34.39%68 592
REGENERON PHARMACEUTICALS33.82%67 216
VERTEX PHARMACEUTICALS-21.68%48 018